title: [Clinical experiences with hyperthermochemotherapy of hepatic metastasis from gastric cancer].
abstract: Thermochemotherapy was performed on gastric cancer cases of hepato-metastasis. The subjects were 12 gastric cancer cases having hepato-metastatic lesions (10 synchronous, 2 heterochronous). Using 8 or 13.58 MHz-dielectric heating apparatus, thermotherapy was carried out for 40-60 min (twice a week, 5-35 times, averaging 12.8 per case) at an intra-tumoral temperature greater than 42 degrees C. Chemotherapy consisted of hepato-arterial infusion of MMC 10 mg/BW, CDDP 75 mg/m2 once per 3-4 weeks and consecutive daily administration p.o. of UFT 800 mg/BW. Effect greater than PR was noted in 75% (9/12) on the whole and in 100% (5/5) and 57% (4/7) for H1-2 and H3, respectively. Mean and 50% survival periods were 9.3 and 7.2 months, respectively, with a one-year survival rate of 38%. Chemotherapy-induced side effects were nausea and vomiting in 83% and leukopenia and thrombopenia in 67%, while the only thermotherapy-induced side effect was subcutaneous fatty tissue necrosis in 3 cases. The above results suggested the effectiveness of the present thermochemotherapy in the treatment of hepato-metastasis of gastric cancer.
authors.affiliation: Surgery II, School of Medicine, Kanazawa University.
authors.forename: Y
authors.initials: Y
authors.lastname: Yonemura
authors.forename: T
authors.initials: T
authors.lastname: Fujimura
authors.forename: M
authors.initials: M
authors.lastname: Urade
authors.forename: S
authors.initials: S
authors.lastname: Takegawa
authors.forename: T
authors.initials: T
authors.lastname: Kamata
authors.forename: S
authors.initials: S
authors.lastname: Fushida
authors.forename: K
authors.initials: K
authors.lastname: Tsugawa
authors.forename: H
authors.initials: H
authors.lastname: Matumoto
authors.forename: N
authors.initials: N
authors.lastname: Matuki
authors.forename: T
authors.initials: T
authors.lastname: Sawa
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005743:Gastrectomy; D006801:Humans; D006979:Hyperthermia, Induced; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011379:Prognosis; D013274:Stomach Neoplasms / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil; D002945:Cisplatin